In our effort to launch an international phase II trial in ARDS (NCT06308926), Medregen has also successfully submitted an IND for a phase II trial to the Chinese NMPA.
30
Oct
MEDREGEN
Clinical stage pharmaceutical company
Phase II ARDS IND Submission China (NMPA)
